We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc and Sumitomo Mitsui Financial Group Inc on Monday agreed to establi ...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire DUBAI, UAE, March 27, 2024 Takeda's 'In Their Shoes' initiative illuminates the daily...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire DUBAI, UAE, March 27, 2024 Takeda's 'In Their Shoes' initiative illuminates the daily...
Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has receive ...
Takeda Pharmaceutical Co Ltd on Monday said profit fell in the first half of its financial year, despite revenue risi ...
Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer trea ...
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older PR...
Takeda Pharmaceutical Co Ltd on Thursday kept its guidance for financial 2024 unchanged, after reporting a 15% drop i ...
Japanese pharmaceutical firm Takeda Pharmaceutical Co Ltd is voluntarily withdrawing its application for approval of ...
Japanese pharma firm Takeda Pharmaceuticals Co Ltd is voluntarily withdrawing its application for approval of a dengu ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 49.35 | 49.35 | 49.35 | 1000 | 49.35 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions